Drug intelligence / Profile preview

MCP435

Development stage: Preclinical
Lead developer: Illexcor Therapeutics
Modality: Small Molecules

Overview

**MCP435** is an investigational small molecule developed by Illexcor Therapeutics as a direct hemoglobin S (HbS) polymerization inhibitor for the treatment of sickle cell disease. It specifically targets the polymerization process of HbS, which is the root cause of red blood cell sickling and vaso-occlusive events in sickle cell disease. Preclinical data demonstrate that MCP435 completely halts ongoing disease pathophysiology in transgenic sickle cell disease mouse models, sustaining >75% inhibition of sickling for 150 minutes under total anoxia conditions[5][7].

Other names: pyrindinyl benzaldehyde

Targets

HbS (Hemoglobin S)

Beyond the preview

Go deeper on MCP435.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MCP435.

Explore the full profile